 |
|
Lithium chloride slows onset of skeletal muscle disorder
March 19, 2008A new UC Irvine study finds that lithium chloride, a drug used to treat bipolar disorder, can slow the development of inclusion body myositis, a skeletal muscle disease that affects the elderly.
In the study by scientists Frank LaFerla and Masashi Kitazawa, mice genetically engineered to have IBM demonstrated markedly better motor function six months after receiving daily doses of lithium chloride, compared with non-treated mice. The muscles in treated mice also had lower levels of a protein that the study linked to muscle inflammation associated with IBM.
These data are the first to show that lithium chloride is a potential IBM therapy.
"Lithium chloride is an approved drug for treating humans. We already know it is safe and can be used by people," said LaFerla, professor of neurobiology and behavior at UCI and co-author of the study. "Given our findings, we believe a clinical trial that tests the effectiveness of lithium chloride on IBM patients should be conducted as soon as possible."
Results of the study appear online this month in the journal Annals of Neurology.
IBM is the most common skeletal muscle disorder among people older than 50. People with IBM experience weakness, inflammation and atrophy of muscles in their fingers, wrists, forearms and quadriceps. There is no cure for IBM, nor is there an effective treatment, according to the National Institutes of Health.
LaFerla, a noted Alzheimer's disease researcher, began studying IBM about 10 years ago after learning the disorders have similar tissue characteristics. In the brain, a buildup of phosphorylated tau protein leads to the development of tangles, one of the two lesions that are hallmarks of Alzheimer's disease. High phospho-tau levels also are present in IBM, though patients do not experience dementia or memory loss. In a previous study, LaFerla found that lithium chloride reduced phospho-tau levels in mice genetically engineered to develop Alzheimer's disease.
LaFerla and his research team then wondered: Could lithium chloride also reduce phospho-tau levels and symptoms in mice with IBM?
First, they sought to determine how the inflammation affects the skeletal muscle fibers. They injected the mice with a drug to trigger muscle inflammation, then put them on tiny treadmills to test their motor function. As expected, mice with inflammation could not keep up with the control mice, indicating reduced motor function. Examining their brain tissue, the scientists discovered the mice with muscle inflammation also had higher levels of phospho-tau.
Through additional testing, they discovered an enzyme called GSK-3 beta was responsible for increasing the tau phosphorylation. Previous studies have shown that same enzyme to cause tau buildup in the Alzheimer's brain.
Next, the scientists sought to block the accumulation of phospho-tau in the IBM mice with the goal of curbing motor function loss. In mice six months of age, one group was fed lithium chloride-laced food for six months, and a second group was fed regular food. At 12 months of age, mice in the first group performed on the treadmill as if they were six months of age, while mice in the second group had reduced motor function. Lithium chloride, the scientists found, blocked the GSK-3 beta enzyme that caused higher levels of phospho-tau.
"The older animals were performing as if they were younger animals," said Kitazawa, a postgraduate researcher of neurobiology and behavior at UCI and co-author of the study. "Lithium chloride was delaying their rate of decline."
The scientists then sought evidence that their results in mice might translate to humans with IBM. They performed tests on human muscle tissue samples and found the GSK-3 beta enzyme again played a role in the phosphorylation of tau. That was not the case, though, in patients with other muscle disorders. "This suggests that our IBM mouse model may have the same skeletal muscle mechanism as in human cases," LaFerla said.
Researcher Dan Trinh of UCI also worked on this study, which was funded by the National Institutes of Health.
The University of California, Irvine
"Lithium chloride is an approved drug for treating humans. We already know it is safe and can be used by people," said LaFerla, professor of neurobiology and behavior at UCI and co-author of the study. "Given our findings, we believe a clinical trial that tests the effectiveness of lithium chloride on IBM patients should be conducted as soon as possible."
Results of the study appear online this month in the journal Annals of Neurology.
IBM is the most common skeletal muscle disorder among people older than 50. People with IBM experience weakness, inflammation and atrophy of muscles in their fingers, wrists, forearms and quadriceps. There is no cure for IBM, nor is there an effective treatment, according to the National Institutes of Health.
LaFerla, a noted Alzheimer's disease researcher, began studying IBM about 10 years ago after learning the disorders have similar tissue characteristics. In the brain, a buildup of phosphorylated tau protein leads to the development of tangles, one of the two lesions that are hallmarks of Alzheimer's disease. High phospho-tau levels also are present in IBM, though patients do not experience dementia or memory loss. In a previous study, LaFerla found that lithium chloride reduced phospho-tau levels in mice genetically engineered to develop Alzheimer's disease.
LaFerla and his research team then wondered: Could lithium chloride also reduce phospho-tau levels and symptoms in mice with IBM?
First, they sought to determine how the inflammation affects the skeletal muscle fibers. They injected the mice with a drug to trigger muscle inflammation, then put them on tiny treadmills to test their motor function. As expected, mice with inflammation could not keep up with the control mice, indicating reduced motor function. Examining their brain tissue, the scientists discovered the mice with muscle inflammation also had higher levels of phospho-tau.
Through additional testing, they discovered an enzyme called GSK-3 beta was responsible for increasing the tau phosphorylation. Previous studies have shown that same enzyme to cause tau buildup in the Alzheimer's brain.
Next, the scientists sought to block the accumulation of phospho-tau in the IBM mice with the goal of curbing motor function loss. In mice six months of age, one group was fed lithium chloride-laced food for six months, and a second group was fed regular food. At 12 months of age, mice in the first group performed on the treadmill as if they were six months of age, while mice in the second group had reduced motor function. Lithium chloride, the scientists found, blocked the GSK-3 beta enzyme that caused higher levels of phospho-tau.
"The older animals were performing as if they were younger animals," said Kitazawa, a postgraduate researcher of neurobiology and behavior at UCI and co-author of the study. "Lithium chloride was delaying their rate of decline."
The scientists then sought evidence that their results in mice might translate to humans with IBM. They performed tests on human muscle tissue samples and found the GSK-3 beta enzyme again played a role in the phosphorylation of tau. That was not the case, though, in patients with other muscle disorders. "This suggests that our IBM mouse model may have the same skeletal muscle mechanism as in human cases," LaFerla said.
Researcher Dan Trinh of UCI also worked on this study, which was funded by the National Institutes of Health.
The University of California, Irvine
UGA researchers discover 'episodic-like' memory in rats
Human memory is a mental scrapbook, filled with moments of luminous happiness or unforgettable sorrow.
More Lithium Chloride Current Events and Lithium Chloride News Articles
 |
Handbook of Lithium and Natural Calcium Chloride by Donald E. Garrett (Author) This book is concerned with two major industrial minerals: Lithium and Calcium Chloride. The geology of their deposits is first reviewed, along with discussions of most of the major deposits and theories of their origin. The commercial mining and processing plants are next described, followed by a review of the rather extensive literature on other proposed processing methods. The more important uses for lithium and calcium chloride are next covered, along with their environmental considerations. This is followed by a brief review of the production statistics for each industry, and some of their compounds' phase data and physical properties. - Describes the chemistry, chemical engineering, geology and mineral processing aspects of lithium and... |
|
LITHIUM CHLORIDE LAB GRADE 100G by Post Apple Scientific Inc. LiCl, CAS#: 7447-41-8, FW: 42.39 | |
 |
SAFT LS26500 3.6V Lithium Thionyl Chloride Battery Saft LS26500 primary lithium cell, is based on the Lithium-Thionyl chloride chemistry. The LS26500 key features are the concentric electrodes construction that enables maximum loading of active materials and corresponding energy. |
 |
The Electromotive Force and Free Energy of Dilution of Lithium Chloride in ... by Mortimer Franklin Spencer (Author) |
 |
Brinkmann Electrolyte Solutions for Metrohm Karl Fischer Titrator Electrodes, Lithium Chloride Electrolyte, 250 mL by Fisher Scientific Electrolyte, Lithium chloride; Saturated in ethanol; Bridge electrolyte for nonaqueous titrations and for Solvotrode electrodes; 250mL |
 |
The Hydration of Ions and the Influence of Viscosity on the Transference Number of Lithium Chloride by Earl Bowman Millard (Author) This volume is produced from digital images created through the University of Michigan University Library's preservation reformatting program. The Library seeks to preserve the intellectual content of items in a manner that facilitates and promotes a variety of uses. The digital reformatting process results in an electronic version of the text that can both be accessed online and used to create new print copies. This book and thousands of others can be found in the digital collections of the University of Michigan Library. The University Library also understands and values the utility of print, and makes reprints available through its Scholarly Publishing Office. |
 |
The Electrolysis Of A Solution Of Lithium Chloride In Pyridine (1908) by Alfred Richard Koch (Author) |
 |
The Electromotive Force And Free Energy Of Dilution Of Lithium Chloride In Aqueous And Alcoholic Solutions by Franklin Spencer Mortimer (Author) |
 |
Lithium: Production and Application of a Fascinating and Versatile Element by Jurgen Deberitz (Author) |
|
Safety considerations of lithium-thionyl chloride cells (SuDoc NAS 1.26:180129) by Subbarao Surampudi (Author) |
| © 2009 BrightSurf.com |